| Literature DB >> 28390561 |
Abstract
Contraception represents an important area of reproductive health for patients with rheumatic diseases given the potential pregnancy risks associated with active disease, teratogenic medications, and severe disease-related damage. A high proportion of patients with rheumatic disease do not use effective contraception. Long-acting contraceptives are most effective. Antiphospholipid-negative patients with stable systemic lupus erythematosus may use oral combined contraceptives. Antiphospholipid-positive patients, or patients with rheumatic disease with other risk factors for thrombosis, should avoid estrogen-containing contraceptives. Contraceptive methods should be addressed by both the rheumatologist and gynecologist to determine the safest, most effective, and most convenient form for each patient.Entities:
Keywords: Antiphospholipid syndrome; Birth control pill; Contraception; Intrauterine device; Long-acting reversible contraception; Systemic lupus erythematosus
Mesh:
Substances:
Year: 2017 PMID: 28390561 DOI: 10.1016/j.rdc.2016.12.001
Source DB: PubMed Journal: Rheum Dis Clin North Am ISSN: 0889-857X Impact factor: 2.670